Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
Marline G HarmsenJurgen M J PiekJohan BultenMurray J CaseyTimothy R RebbeckMarian J MouritsMark H GreeneBrigitte F M SlangenMarc van BeurdenLeon F A G MassugerNicoline HoogerbruggeJoanne A de HulluPublished in: Cancer (2018)
Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, usually within 5 years. Data have suggested that surgery at a younger age lowers the rates of peritoneal carcinomatosis. These data can be used in the gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete salpingectomy. Detailed histopathological examination of specimens removed during RRSO is essential. Cancer 2018;124:952-9. © 2018 American Cancer Society.
Keyphrases
- minimally invasive
- coronary artery bypass
- papillary thyroid
- surgical site infection
- electronic health record
- breast cancer risk
- squamous cell
- squamous cell carcinoma
- coronary artery disease
- machine learning
- percutaneous coronary intervention
- young adults
- lymph node metastasis
- human immunodeficiency virus
- fine needle aspiration